Cargando…

DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS

The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the infecting viral strain. Bioinformatics programs that predict coreceptor usage could provide an alternative method to screen candidates for treatment with CCR5 antagonists, particularly in countries wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arruda, Liã Bárbara, de Araújo, Marilia Ladeira, Martinez, Maira Luccia, Gonsalez, Claudio Roberto, Duarte, Alberto José da Silva, Coakley, Eoin, Lie, Yolanda, Casseb, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto de Medicina Tropical 2014
Materias:
HIV
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131812/
https://www.ncbi.nlm.nih.gov/pubmed/25076427
http://dx.doi.org/10.1590/S0036-46652014000400003
_version_ 1782330522777681920
author Arruda, Liã Bárbara
de Araújo, Marilia Ladeira
Martinez, Maira Luccia
Gonsalez, Claudio Roberto
Duarte, Alberto José da Silva
Coakley, Eoin
Lie, Yolanda
Casseb, Jorge
author_facet Arruda, Liã Bárbara
de Araújo, Marilia Ladeira
Martinez, Maira Luccia
Gonsalez, Claudio Roberto
Duarte, Alberto José da Silva
Coakley, Eoin
Lie, Yolanda
Casseb, Jorge
author_sort Arruda, Liã Bárbara
collection PubMed
description The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the infecting viral strain. Bioinformatics programs that predict coreceptor usage could provide an alternative method to screen candidates for treatment with CCR5 antagonists, particularly in countries with limited financial resources. Thus, the present study aims to identify the best approach using bioinformatics tools for determining HIV-1 coreceptor usage in clinical practice. Proviral DNA sequences and Trofile results from 99 HIV-1-infected subjects under clinical monitoring were analyzed in this study. Based on the Trofile results, the viral variants present were 81.1% R5, 21.4% R5X4 and 1.8% X4. Determination of tropism using a Geno2pheno([coreceptor]) analysis with a false positive rate of 10% gave the most suitable performance in this sampling: the R5 and X4 strains were found at frequencies of 78.5% and 28.4%, respectively, and there was 78.6% concordance between the phenotypic and genotypic results. Further studies are needed to clarify how genetic diversity amongst virus strains affects bioinformatics-driven approaches for determining tropism. Although this strategy could be useful for screening patients in developing countries, some limitations remain that restrict the wider application of coreceptor usage tests in clinical practice.
format Online
Article
Text
id pubmed-4131812
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Instituto de Medicina Tropical
record_format MEDLINE/PubMed
spelling pubmed-41318122014-08-14 DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS Arruda, Liã Bárbara de Araújo, Marilia Ladeira Martinez, Maira Luccia Gonsalez, Claudio Roberto Duarte, Alberto José da Silva Coakley, Eoin Lie, Yolanda Casseb, Jorge Rev Inst Med Trop Sao Paulo HIV The clinical application of CCR5 antagonists involves first determining the coreceptor usage by the infecting viral strain. Bioinformatics programs that predict coreceptor usage could provide an alternative method to screen candidates for treatment with CCR5 antagonists, particularly in countries with limited financial resources. Thus, the present study aims to identify the best approach using bioinformatics tools for determining HIV-1 coreceptor usage in clinical practice. Proviral DNA sequences and Trofile results from 99 HIV-1-infected subjects under clinical monitoring were analyzed in this study. Based on the Trofile results, the viral variants present were 81.1% R5, 21.4% R5X4 and 1.8% X4. Determination of tropism using a Geno2pheno([coreceptor]) analysis with a false positive rate of 10% gave the most suitable performance in this sampling: the R5 and X4 strains were found at frequencies of 78.5% and 28.4%, respectively, and there was 78.6% concordance between the phenotypic and genotypic results. Further studies are needed to clarify how genetic diversity amongst virus strains affects bioinformatics-driven approaches for determining tropism. Although this strategy could be useful for screening patients in developing countries, some limitations remain that restrict the wider application of coreceptor usage tests in clinical practice. Instituto de Medicina Tropical 2014 /pmc/articles/PMC4131812/ /pubmed/25076427 http://dx.doi.org/10.1590/S0036-46652014000400003 Text en http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle HIV
Arruda, Liã Bárbara
de Araújo, Marilia Ladeira
Martinez, Maira Luccia
Gonsalez, Claudio Roberto
Duarte, Alberto José da Silva
Coakley, Eoin
Lie, Yolanda
Casseb, Jorge
DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title_full DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title_fullStr DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title_full_unstemmed DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title_short DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
title_sort determination of viral tropism by genotyping and phenotyping assays in brazilian hiv-1-infected patients
topic HIV
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131812/
https://www.ncbi.nlm.nih.gov/pubmed/25076427
http://dx.doi.org/10.1590/S0036-46652014000400003
work_keys_str_mv AT arrudaliabarbara determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT dearaujomarilialadeira determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT martinezmairaluccia determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT gonsalezclaudioroberto determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT duartealbertojosedasilva determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT coakleyeoin determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT lieyolanda determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients
AT cassebjorge determinationofviraltropismbygenotypingandphenotypingassaysinbrazilianhiv1infectedpatients